Physician profile
Kerrily Gresham Murphy
NPI 1700317377
$4,974.05
in general payments reported to CMS, 2019-2025
32 companies · $912 in 2025
The $912 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $327 · 2022: $1,107 · 2023: $1,203 · 2024: $1,424 · 2025: $912.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,539.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $975.40 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $498.97 | 2021-2025 | |
| Lilly USA, LLC | $453.62 | 2021-2025 | Mounjaro, Trulicity, Emgality |
| Novo Nordisk INC | $449.80 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $368.60 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $308.34 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $209.15 | 2021-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $183.67 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Exact Sciences Corporation | $170.89 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $162.66 | 2023-2025 | Otezla, Repatha, Repatha |
| Dexcom, INC. | $153.31 | 2023-2025 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $129.41 | 2022-2025 | Austedo Xr, Austedo, Austedo Xr |
| Boston Scientific Corporation | $112.64 | 2021-2024 | |
| Shield Therapeutics INC | $100.84 | 2023-2025 | Accrufer |
| Otsuka America Pharmaceutical, INC. | $98.04 | 2024 | Rexulti |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $82.97 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $81.04 | 2021-2024 | Trintellix |
| Axsome Therapeutics, INC. | $60.99 | 2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $59.99 | 2025 | Caplyta |
| Antares Pharma, INC. | $44.17 | 2024 | Xyosted, Tlando |
| Supernus Pharmaceuticals, INC. | $43.48 | 2022 | Tlando, Xyosted |
| Sanofi-Aventis U.S. LLC | $37.15 | 2023 | |
| Tris Pharma INC | $22.95 | 2025 | Dyanavel Xr |
| Halozyme INC | $21.07 | 2023 | |
| Neurelis, INC. | $20.16 | 2024 | Valtoco |
| Amarin Pharma, INC. | $19.97 | 2021 | |
| Sumitomo Pharma America, INC. | $19.44 | 2023 | Gemtesa |
| Horizon Therapeutics Plc | $18.59 | 2023 | Krystexxa |
| Janssen Pharmaceuticals, INC | $17.94 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.36 | 2025 | Jardiance |
| Idorsia Pharmaceuticals US INC | $17.10 | 2024 | Quviviq |
| Lundbeck LLC | $14.34 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerrily Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.